Logo image of VTYX

VENTYX BIOSCIENCES INC (VTYX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:VTYX - US92332V1070 - Common Stock

9.43 USD
-0.18 (-1.87%)
Last: 11/21/2025, 8:05:07 PM
9.6496 USD
+0.22 (+2.33%)
After Hours: 11/21/2025, 8:05:07 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to VTYX. VTYX was compared to 192 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for VTYX as it has an excellent financial health rating, but there are worries on the profitability. VTYX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

VTYX had negative earnings in the past year.
VTYX had a negative operating cash flow in the past year.
In the past 5 years VTYX always reported negative net income.
In the past 5 years VTYX always reported negative operating cash flow.
VTYX Yearly Net Income VS EBIT VS OCF VS FCFVTYX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

VTYX's Return On Assets of -51.75% is on the low side compared to the rest of the industry. VTYX is outperformed by 60.94% of its industry peers.
VTYX has a Return On Equity (-56.85%) which is in line with its industry peers.
Industry RankSector Rank
ROA -51.75%
ROE -56.85%
ROIC N/A
ROA(3y)-49.18%
ROA(5y)-2852.36%
ROE(3y)-54.31%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VTYX Yearly ROA, ROE, ROICVTYX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -5K -10K

1.3 Margins

VTYX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VTYX Yearly Profit, Operating, Gross MarginsVTYX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for VTYX has been increased compared to 1 year ago.
Compared to 5 years ago, VTYX has more shares outstanding
There is no outstanding debt for VTYX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VTYX Yearly Shares OutstandingVTYX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
VTYX Yearly Total Debt VS Total AssetsVTYX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 15.44 indicates that VTYX is not in any danger for bankruptcy at the moment.
VTYX has a better Altman-Z score (15.44) than 89.06% of its industry peers.
VTYX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 15.44
ROIC/WACCN/A
WACCN/A
VTYX Yearly LT Debt VS Equity VS FCFVTYX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 19.12 indicates that VTYX has no problem at all paying its short term obligations.
VTYX's Current ratio of 19.12 is amongst the best of the industry. VTYX outperforms 89.58% of its industry peers.
A Quick Ratio of 19.12 indicates that VTYX has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 19.12, VTYX belongs to the best of the industry, outperforming 89.58% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 19.12
Quick Ratio 19.12
VTYX Yearly Current Assets VS Current LiabilitesVTYX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

VTYX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.44%, which is quite impressive.
EPS 1Y (TTM)36.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 8.88% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y14.29%
EPS Next 2Y1.18%
EPS Next 3Y1.51%
EPS Next 5Y8.88%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VTYX Yearly Revenue VS EstimatesVTYX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
VTYX Yearly EPS VS EstimatesVTYX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VTYX. In the last year negative earnings were reported.
Also next year VTYX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VTYX Price Earnings VS Forward Price EarningsVTYX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VTYX Per share dataVTYX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.18%
EPS Next 3Y1.51%

More info and screens

0

5. Dividend

5.1 Amount

VTYX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VENTYX BIOSCIENCES INC

NASDAQ:VTYX (11/21/2025, 8:05:07 PM)

After market: 9.6496 +0.22 (+2.33%)

9.43

-0.18 (-1.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-04 2026-02-04/amc
Inst Owners68.54%
Inst Owner Change-1.62%
Ins Owners4.11%
Ins Owner Change0%
Market Cap672.45M
Revenue(TTM)N/A
Net Income(TTM)-119.03M
Analysts81.33
Price Target13.99 (48.36%)
Short Float %8.99%
Short Ratio1.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.89%
Min EPS beat(2)20.73%
Max EPS beat(2)21.05%
EPS beat(4)4
Avg EPS beat(4)18.2%
Min EPS beat(4)5.28%
Max EPS beat(4)25.73%
EPS beat(8)7
Avg EPS beat(8)15.19%
EPS beat(12)8
Avg EPS beat(12)5.4%
EPS beat(16)11
Avg EPS beat(16)-37.72%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)10.39%
PT rev (3m)1.19%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.53%
EPS NY rev (1m)0.71%
EPS NY rev (3m)11.84%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.21
P/tB 3.21
EV/EBITDA N/A
EPS(TTM)-1.5
EYN/A
EPS(NY)-1.93
Fwd EYN/A
FCF(TTM)-1.48
FCFYN/A
OCF(TTM)-1.48
OCFYN/A
SpS0
BVpS2.94
TBVpS2.94
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -51.75%
ROE -56.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-49.18%
ROA(5y)-2852.36%
ROE(3y)-54.31%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr -21.55%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.12
Quick Ratio 19.12
Altman-Z 15.44
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)216.42%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36%
EPS Next Y14.29%
EPS Next 2Y1.18%
EPS Next 3Y1.51%
EPS Next 5Y8.88%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y29.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year28.18%
EBIT Next 3Y9.01%
EBIT Next 5YN/A
FCF growth 1Y30.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.2%
OCF growth 3YN/A
OCF growth 5YN/A

VENTYX BIOSCIENCES INC / VTYX FAQ

Can you provide the ChartMill fundamental rating for VENTYX BIOSCIENCES INC?

ChartMill assigns a fundamental rating of 3 / 10 to VTYX.


Can you provide the valuation status for VENTYX BIOSCIENCES INC?

ChartMill assigns a valuation rating of 0 / 10 to VENTYX BIOSCIENCES INC (VTYX). This can be considered as Overvalued.


Can you provide the profitability details for VENTYX BIOSCIENCES INC?

VENTYX BIOSCIENCES INC (VTYX) has a profitability rating of 0 / 10.